SUMMARY Background
Iron deficiency anaemia (IDA) is a common complication of inflammatory bowel disease (IBD) associated with reduced quality of life and increased hospitalisation rates. While the best way of treating IDA in IBD patients is not clearly established, current European guidelines recommend intravenous iron therapy in IBD patients with severe anaemia or intolerance to oral iron compounds.
Aim
To compare the efficacy and tolerability of different intravenous iron formulations used to treat IDA in IBD patients in a systematic review and Bayesian network meta-analysis (NMA), PROSPERO registration number: 42016046565.
Methods
In June 2016, we systematically searched for studies analysing efficacy and safety of intravenous iron for IDA therapy in IBD. Primary outcome was therapy response, defined as Hb normalisation or increase ≥2 g/dL.
INTRODUCTION Anaemia is the most frequent systemic complication of inflammatory bowel disease (IBD), [1] [2] [3] its estimated prevalence ranging from 6% to 74%. 2, 4, 5 Not only does anaemia negatively impact physical, emotional and cognitive functions and quality of life but it has also been shown to increase hospitalisation rates and time lost from work. 6, 7 While anaemia is polyaetiological, it is most commonly a result of iron deficiency (iron deficiency anaemia, IDA), chronic inflammation (anaemia of chronic disease, ACD) or a combination of both. 8 Iron deficiency has been reported to occur in up to 90% of IBD patients. 9, 10 Its main causes include chronic blood loss from ulcerated intestinal mucosa, impaired gastrointestinal iron absorption as a consequence of short bowel syndrome, low dietary intake due to loss of appetite during IBD flares and inflammationdriven blockage of intestinal iron acquisition and macrophage iron reutilisation. 11, 12 Oral iron compounds are often of limited efficacy, 13 being associated with frequent gastrointestinal side effects and poor compliance in IBD patients. In an 8-week study comparing oral iron with iron dextran, Khalil et al. 14 reported that oral iron (like iron dextran) had no effect on disease activity. On the other hand, several studies have shown ingested iron to exacerbate inflammation by altering the gut microbiome and increasing the permeability of the intestinal epithelium. [15] [16] [17] However, severely increased inflammatory activity has been demonstrated to occur, as a rule, only after at least 3-6 months of oral iron treatment. 18 Modern intravenous iron compounds have been demonstrated to be safe and effective in IBD patients, facilitating rapid correction of haemoglobin levels and repletion of body iron stores. 9, 19, 20 According to guidelines issued by the European Crohn's and Colitis Organisation (ECCO), intravenous iron should therefore be considered first-line therapy for IBD patients with moderate to severe IDA (Hb <10 g/dL) and active disease, while oral therapy can be administered to patients with mild anaemia and clinically inactive disease who have not previously shown intolerance to oral iron. 3 Since several studies have
shown that even mild anaemia can considerably impact quality of life, 21 regular iron status assessment and adequate treatment of anaemia are a vital aspect of routine IBD therapy. Current intravenous iron formulations include high or low molecular weight iron dextran (IDX), ferric gluconate, iron isomaltoside (ISM), iron sucrose/saccharate (IS), ferumoxytol and ferric carboxymaltose (FCM). All share a similar, albeit for each compound unique, structure, containing a core of iron-hydroxide gel encased in a carbohydrate shell which serves to stabilise the core and regulate the speed of iron release. It has been suggested that toxic effects of intravenous iron may result from the release of free iron, which is directly proportional to the rate of iron release from the core. 22 Intravenous iron compounds differ in terms of the size of the core and the composition and density of the surrounding carbohydrate. [22] [23] [24] Although these differences are slight, they may result in considerable variations in the efficacy and tolerability of intravenous iron formulations. The aim of our research was to investigate and summarise the comparative efficacy and tolerability of different types of intravenous iron used to treat iron deficiency anaemia in IBD patients in a systematic review, and to compare these intravenous iron compounds (directly or indirectly) using a network meta-analysis.
MATERIALS AND METHODS
The present review was conducted in keeping with the current guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 25 The PROSPERO registration number is 42016046565.
Information sources and search A literature search was performed in the electronic bibliographic databases, PUBMED, SCOPUS, Web of Science and the Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL) and Cochrane Methodology Register) to identify original studies analysing the efficacy and safety of intravenous iron as monotherapy for iron deficiency anaemia in patients with IBD. The search strategy included terms relating to or describing the different types of intravenous iron, anaemia and inflammatory bowel disease, as follows: "Inflammatory bowel disease/ulcerative colitis/crohn" and "anaemia/anemia" and "intravenous iron/parenteral iron/iron dextran/iron sucrose/iron saccharate/iron isomaltoside/ferric carboxymaltose/ferric gluconate/ferumoxytol". In order to find the maximum number of papers, no publication date restrictions were imposed in any database. The last search was completed in June 2016. Only publications in English language were included.
Eligibility criteria
Original prospective and retrospective studies (e.g. randomised, controlled trials (RCTs), nonrandomised trials, uncontrolled trials, cohort studies, case studies) with a minimum observation time of 4 weeks and published in English as full papers were included. Abstracts reporting as yet unpublished studies were also considered if sufficient data were reported. Studies reporting both included and excluded populations were considered only if data specific to subjects meeting the above-defined inclusion criteria for this systematic review could be extracted (e.g. data for subjects receiving intravenous iron as monotherapy in a trial comparing intravenous iron alone vs. intravenous iron with additional EPO/ESA administration, or data for IBD patients from a trial of both IBD and non-IBD patients). Similarly, individual treatment phases (e.g. from crossover studies) were considered only if baseline and outcome data for the treatment phase was available and our inclusion criteria were otherwise met. Review articles, nonhuman studies, case reports, articles not reporting data on haematopoietic response and studies not published in English were not considered. In addition, studies carried out exclusively in children/adolescents or pregnant/lactating women were excluded.
Study selection
All studies identified via the database search were assessed for relevance to the review based on the information contained in the title, abstract and description/ MESH headings by two independent reviewers. In case of uncertainty regarding a study's suitability for inclusion, a third independent reviewer was consulted, until consensus was reached. For all studies/abstracts meeting the inclusion criteria, full texts were retrieved. If eligibility remained unclear based on the title, abstract and description/MESH headings, the study was retrieved for further clarification.
Data extraction
At a minimum, the following data were extracted from each study and summarised in tabular form: author's name, publication year, title, length of study, number of participants, number of participants who were given intravenous iron therapy, haematological inclusion criteria of participants [i.e. haemoglobin (Hb), serum ferritin, transferrin saturation prior to intravenous iron therapy], intervention and comparator, iron dosage, means of calculation of iron dosage (e.g. Ganzoni or other formula), post-intervention efficacy (i.e. Hb, serum ferritin, transferrin saturation after intravenous iron therapy, response rate) and safety outcome values, that is, the number and type of adverse events and serious adverse events. Response rate for this review was defined as normalisation of Hb or increase in Hb of ≥2 g/dL compared to baseline.
Two authors reviewed and extracted the data independently. Differences in opinion between these two were resolved by a third reviewer.
Risk of bias assessment
The risk of bias of the eligible studies was assessed using the Cochrane Collaboration's Risk of Bias tool in Review Manager (RevMan 5 -http://tech.cochrane.org/revman). Bias risk assessment was performed with reference to the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and any other detectable bias.
Outcome measures
The primary outcome measure was the proportion of patients showing haematopoietic response, defined as normalisation of Hb levels or an increase in Hb of ≥2 g/dL, compared to baseline. Secondary outcome measure was the pooled total of drug-related adverse events and serious adverse events in proportion to the total evaluated safety population, for each respective compound. In case of unclear or conflicting data concerning causal relationship with the study drug, at a minimum, all events reported to be probably or certainly drugrelated were included in the analysis. If study data were presented as the number of patients experiencing adverse events, rather than the actual number of events, this was taken to be the number of AEs, if not otherwise stated.
Network meta-analysis Network meta-analysis, also known as multiple treatment comparison or mixed treatment comparison, is a statistical technique that allows both direct and indirect comparisons to be undertaken. [26] [27] [28] [29] Network meta-analysis allows the comparative evaluation of two or more different treatments which may have never been subjected to direct comparison in a clinical trial, but have been compared to a common comparator. By means of an adjusted indirect treatment comparison, network metaanalysis exploits the direct effects of the two treatments vs. the common comparator to estimate indirect treatment effects. Through inclusion of both direct and indirect data in an evidence synthesis, network meta-analysis optimises the accuracy of the treatment efficacy evaluation. 30 Randomised, controlled trials (RCTs) can thus be summarised by network meta-analysis. Homogeneity, transitivity (similarity) and consistency are fundamental assumptions that are influential to the results of network meta-analysis. Homogeneity requires the effect of treatments to be similar across trials. 31, 32 Transitivity requires that relative treatment effects are assumed to be exchangeable, 32 implying that information for an indirect comparison between treatments A and B can be obtained via another treatment C, using the direct evidence of studies of A vs. C and B vs. C. This assumption cannot be tested statistically, but its validity can be evaluated in a conceptual and epidemiological manner. 33, 34 The statistical manifestation of transitivity is called consistency. 29 Checking the network for consistency constitutes an additional method of indirectly assessing the plausibility of the transitivity assumption. 34 Consistency requires that evidence from both direct and indirect comparisons is in agreement, or that both direct and indirect comparisons estimate the same effect. 35 Statistical inconsistency can thus be considered another form of heterogeneity: Heterogeneity results from the variation in effect modifiers within a treatment comparison, while inconsistency results from the variation in effect modifiers across different treatment comparisons. One measure of heterogeneity is I 2 , a statistic using the Higgins and Thompson method to indicate the percentage of variance attributable to study heterogeneity (low heterogeneity, 25%; moderate, 50%; and high, 75%). 36 A second strategy for gauging whether or not statistical heterogeneity is present is to apply both fixed-effect and random-effect models to the data and then compare the results using a measure of model fit such as the deviance information criterion. 35, 37 A better model fit for the random-effect model is an indication of heterogeneity. Consistency can be assessed by comparing the standard network consistency model to an inconsistency or unrelated mean effects model, or by using the node-splitting approach as proposed by Dias et al. (2010) . 35 Although inference based on network meta-analysis can be made in both frequentist and Bayesian frameworks, Bayesian network meta-analysis is more commonly used, as researchers are able to incorporate prior knowledge for parameters of interest and a rich and flexible family of models can be fitted. It also allows assessment of rank probabilities (the probability that each treatment is best, second best and so on) for decision making. 32 The Akaike Information Criterion (AIC) and the Bayesian Information Criterion (BIC) are most commonly used to choose which statistical model represents a better fit for a particular set of observations, and to differentiate between alternative models. The Deviance Information Criterion, Bayesian version of the AIC and also related to the BIC, is a method that has been generated to identify the better model within the Bayesian framework. 30, 38 In this study, the network meta-analysis was performed within a Bayesian framework using Markov chain Monte Carlo methods using R version 3.3.1 with the gemtc package.
In each Markov chain Monte Carlo run, every treatment is ranked according to its estimated magnitude. Then, the proportion of Markov chain Monte Carlo cycles in which the treatment k ranks first gives the probability that this specific treatment is the best among all K-treatments compared. 30 However, this denotation only represents one possibility without certainty. 39 Although treatment rankings and probabilities are arguably easy to interpret, their interpretability is limited by the fact that they are driven predominantly by the estimated effect sizes, and that standard errors play an unduly small role in determining their position. 40, 41 It is advised to observe the estimated effects first and use the rankings only as a supplementary measure. 41 Kibret et al. suggest that health researchers should use rank probabilities cautiously in making important decisions.
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Bayesian network meta-analysis was performed with the five eligible RCTs to calculate the efficacy of each iron therapy relative to all other comparators. Results were presented as ORs related with response rate to evaluate treatment efficacy. Our primary outcome measure, response rate, was measured as the percentage of IBD patients showing response (defined as normalisation of Hb or increase in Hb of ≥2 g/dL) to treatment for iron deficiency anaemia, from baseline to endpoint.
RESULTS
A summary of the database research and selection process is presented in Figure 1 (PRISMA Flow Diagram). The systematic search yielded a total of 1894 studies, of which 322 remained after removal of duplications. (The terms anemia and anaemia, although interchangeable in most databases, were known by the authors to retrieve differing numbers of papers in the Pubmed database. Both terms were therefore entered separately in the Pubmed literature search). After detailed review of these abstracts, full papers of 50 studies were retrieved for extensive profiling. In total, 15 studies were ultimately determined to be eligible. These 15 studies were included in our systematic review.
Study characteristics
Characteristics of the 15 studies included in the systematic review are summarised in Table 1 were assessed against oral iron. In one RCT, FCM was compared to IS 22 and lastly, in one RCT, IS was compared to IS in combination with erythropoietin (EPO). 42 Since the present review focused solely on intravenous iron compounds as monotherapy, the latter study was excluded from the network meta-analysis on the grounds of the comparator group receiving EPO combination therapy. However, the IS-only group was included in the systematic review. As no RCTs studying IDX were found to be eligible, we were not able to include IDX in the network meta-analysis. Besides a total of six RCTs, nine nonrandomised, case-control, cohort and uncontrolled studies of various designs were included in the systematic review. 14, 43-46, 48-51 One small crossover study 56 was carefully considered for inclusion but finally excluded on the grounds of a lack of sufficient data on response rates and missing confirmation of anaemia before the second study phase. In summary, the systematic review included six RCTs and nine studies of other designs assessing the efficacy of specific intravenous iron solutions.
Efficacy outcomes
In four RCTs comparing intravenous iron formulations (FCM, IS and ISM) vs. oral iron compounds, 52-55 efficacy outcomes were always superior in the intravenous iron group. Only one RCT directly compared two different intravenous iron products, FCM and IS, 22 and in this trial, efficacy outcomes of FCM were superior to those of IS. In the one RCT comparing IS as monotherapy vs. EPO therapy combined with IS, 42 the IS+EPO group had slightly better outcomes. Concomitant EPO therapy is recommended only if there is insufficient response to intravenous iron alone. One case-control 43 and one prospective nonrandomised, controlled 48 study compared IS with oral iron.
In both of these studies, oral iron showed better efficacy outcomes than IS. In the one and only comparative study concerning IDX, a case-control study 14 comparing IDX with oral iron, the oral iron group had better efficacy outcomes. Six studies included in the systematic review assessed FCM, 44, 49, 50 IS 45, 51 or IDX 46 alone. According to the outcomes of these studies, response rates were 70-86% for FCM, 65-80% for IS and 51% for IDX (one study). AE, adverse event; BW, body weight; FCM, ferric carboxymaltose; GI, gastrointestinal; IDX, iron dextran; IS, iron sucrose; IS+EPO, iron sucrose in combination with erythropoietin; ISM, iron isomaltoside; IV, intravenous; SAE, serious adverse event; SPC, summary of product characteristics; TSAT, transferrin saturation; ULN, upper limit of normal.
In total, the systematic review included five studies with 505 patients for FCM, 22 
Safety outcomes
In general, intravenous iron products were reported to be well tolerated, with some risk of adverse events. FCM was well tolerated and associated with minimal risk of side effects. In total, 543 patients were included in the FCM safety set in five studies 22, 44, 49, 50, 52 : Of 543 patients, 65 (12.0%) experienced adverse events associated with FCM treatment, the most common being transient increase in liver enzymes (2.2%), headache (1.7%), hyperferritinaemia (1.3%) and hypophosphataemia (1.7%). In addition, one serious adverse event (1/543, 0.2%) in a patient receiving FCM (pulmonary embolism) was considered by the treating physician to be drug related. Eight studies evaluated the safety profile of IS, with a total population of 471: adverse events occurred in 72/471 (15.3%) and one "possibly" drug-related serious adverse event (thrombocytopoenia) was noted. The most common side effects were burning at site of venepuncture (1.5%), headache, bitter taste (0.8%), iron overload, transient fever and paraesthesia (0.6%). For IDX, there were two studies with a total of 83 patients in the safety set. While no serious adverse events were reported in association with IDX application, it must be noted that the study of Koutroubakis et al. 46 included 10 patients (20%) who received prophylactic pre-medication with corticosteroids. Treatment-related adverse events were reported in 10/83 (12%), most commonly anaphylactoid reactions (3.6%), nausea (3.6%) and dyspnoea (2.4%). For ISM, only one study was available, including 223 patients. While side effects were reported to have occurred in 38/223 (17%), no specific information about the most common adverse events was reported. One ISM-related serious adverse event (grand mal convulsion) was reported (1/223, 0.5%).
As regards comparative tolerability, only one study 22 made a direct comparison of two different intravenous iron formulations (IS and FCM). In this RCT, rates of adverse events/serious adverse events for IS and FCM showed no significant differences. In five out of six of the other studies comparing oral iron to intravenous iron, 14, 48, 52, 53, 55 the tolerability of intravenous iron formulations (FCM, IS, IDX) was superior to that of oral iron. However, in the one and only comparative study 54 of ISM vs. oral iron, the safety results of oral iron were superior to those of ISM.
Infusion and dosage
In five studies assessing FCM, patients received one to three 15-min intravenous applications in single doses of 500-1000 mg per infusion. 22, 44, 49, 50, 52 In contrast, IS was applied in single doses of 200 mg in 1-11 infusions over 30 min. 22, 42, 43, 45, 48, 51, 53, 55 While data concerning the number of infusions of IDX were not clear in the two studies included, 14, 46 one mentioned that 53 infusions in total had been applied to 36 patients. 14 Infusion duration in the other study varied between 4 and 6 h, that is, considerably longer than IS and FCM. 14, 46 In the one study of ISM, while the total number of infusions was not stated, intravenous applications of up to 1000 mg were administered once a week. 54 
Risk of bias assessment
Bias assessment for RCTs included in the network metaanalysis, performed using the Cochrane Collaboration's tool, is presented in Figure 2 ( Figure S1 ). Participants and personnel were not blinded to the interventions in four of five studies. 22, [52] [53] [54] [55] There was incomplete outcome data reporting for two studies. 22, 53 In one of these studies, 53 final Hb and ferritin values were presented only graphically and no standard deviation was reported. In another study 22 , Hb, ferritin and transferrin saturation values were presented graphically and no mean values or standard deviations were reported. In four studies, 22, 52, 54, 55 data analyses were carried out by an external clinical trial company on behalf of the sponsor, and in three trials, it is unclear from the manuscripts whether the authors had full access to collected data. 52, 54, 55 Both of the latter cases were considered reporting bias with unclear risk.
Bayesian network meta-analysis
Bayesian network meta-analysis was performed on the five eligible RCTs, with a total patient population of 1143, to calculate the relative efficacy of all included iron therapies ( Figure S2 ). Based on the pair-wise metaanalysis of two RCTs comparing IS vs. oral iron, the statistical heterogeneity analysis showed nonsignificant (P > 0.10) statistical heterogeneity among the studies (I 2 = 10%).
We used deviance information criterion (DIC) statistics to compare the fixed-effect model (DIC=18.215) with the random-effect model (DIC=18.585). Thus, the fixedeffect model was found to offer a better model fit, confirming the low level of heterogeneity. The node-splitting approach, as proposed by Dias et al. (2010) , 35 was used to check consistency. Significant inconsistency would be indicated if node-splitting analysis derived P < 0.05. Using the fixed-effect model, there was no evidence of inconsistency between the direct and indirect evidence in all networks, that is, all P-values were without statistical significance at 5%. Furthermore, we identified no evidence of inconsistency in the network meta-analysis when comparing the standard network consistency model (DIC = 18.215) to a model assuming inconsistency (DIC = 19.265). Figure 3 shows the results of the Bayesian network meta-analysis, expressed as ORs based on response rate with 95% credible intervals (CrIs), which serve the same purpose as confidence intervals in the context of the Bayesian framework. The only intravenous iron therapy which was shown to have a significantly superior efficacy compared with oral iron was FCM [OR = 1.9 with 95% CrI: (1.2; 3.2)]: The response rate for FCM was 1.9 times that of oral iron therapy, and the odds ratio for response to oral iron was approximately half of the odds of response in patients treated with FCM. The other intravenous iron compounds (IS, ISM) also had better response rates than oral iron, but without statistical significance [OR = 1.3 with 95% CrI: (0.79;2.2) for IS, OR = 1.3 with 95% CrI (0.80;2.1) for ISM]. Concerning efficacy, no statistically significant difference was found when comparing FCM, ISM and IS, but the analysis showed FCM to have better efficacy results than the other two intravenous formulations [OR = 0.69 with 95% CrI: (0.34;1.4) for ISM, OR = 0.70 with 95% CrI: (0.48;1.0) for IS]. Table 2 shows rank probabilities of the five treatments. FCM was the most effective treatment, IS was the second best treatment, and ISM was third best. OI was the least effective therapy. While our statistical evaluations of heterogeneity and transitivity for the network meta-analysis support the validity of this ranking, additional randomised trials are needed to support these data and increase the level of evidence.
DISCUSSION
Although anaemia in IBD is multifaceted and its root causes need to be identified on an individual basis, iron deficiency is by far the most common aetiology. Oral iron supplementation was for many years the treatment of choice. Iron ingestion, however, is associated with gastrointestinal side effects 10, 57 and has been shown to impact the composition of the microbiome, 58 which has a central role in the pathogenesis of IBD. 59 Besides established oral compounds such as ferrous sulphate, therapeutic options for IDA in IBD include a variety of different intravenous iron formulations. While in the past, products such as high molecular weight (HMW) iron dextran were associated with major safety concerns, newer intravenous iron compounds such as IS, FCM and ISM have been shown to be not only effective but also generally safe. Furthermore, the administration of intravenous iron has been demonstrated to achieve more rapid and effective repletion of body iron stores than oral iron supplementation 11 . According to the most recent guidelines for the treatment of IDA in IBD patients issued by the European Crohn's and Colitis Organisation (ECCO) in 2015, intravenous iron replacement is recommended as first-line therapy in patients with moderate to severe IDA (Hb <10) and in patients who have shown intolerance or nonresponse to oral iron. 57 The present study aimed to investigate, summarise and compare data from published clinical and observational trials studying the efficacy and tolerability of different intravenous iron formulations used to treat IDA in IBD patients, seeking to improve the level of evidence supporting the application of modern intravenous iron compounds. As only a small number of the published RCTs on intravenous iron have a population comprising exclusively adult IBD patients, and only one of these directly compares two different intravenous compounds, we collected additional evidence for the systematic review and evaluated the eligible RCTs in a network meta-analysis to verify the data analysis. Due to unavailability of RCTs, IDX was not included in the network meta-analysis. Ferumoxytol (not yet approved in Europe for IDA in IBD patients), was excluded from the analysis due to the absence of eligible publications. The superiority of intravenous iron over oral iron for the treatment of IDA in IBD has already been shown in three separate meta-analyses. 9, 19, 58 In line with thisalthough three studies included in our systematic review did show greater effectiveness for oral compounds -our overall analysis demonstrated intravenous iron to be generally more effective than oral iron. 14, 43, 48 Statistical significance could be shown only for FCM. Our comparative evaluation of intravenous iron compounds showed FCM to be most effective, followed by IS and ISM respectively. Our finding is consistent with the only available randomised comparative trial of FCM with IS, 22 which showed FCM to have superior efficacy.
Although data for IDX were sparse, they indicated it to be more effective than oral iron but less effective than FCM, IS or ISM.
In the recent literature, we were able to identify only one systematic review discussing the comparable efficacy of intravenous iron products, in which Rognoni et al. 60 showed a significantly superior efficacy for FCM in terms Table 2 | Rank probability matrix, as calculated by the Markov chain Monte Carlo method (see methods section), displaying estimated ranks of the different treatment effects. For each treatment, the table shows the probability that treatment effect was the best, 2nd best, 3rd best or 4th best of the four treatments compared of Hb increase compared with ferrous sulphate (oral) and ferric gluconate, an intravenous iron compound not currently approved for use in IBD patients. This largescale review also employed network meta-analysis but included no data for ISM or IDX, and its population was not limited to IBD patients. In contrast to Rognoni 60 , we undertook an objective comparative assessment of all intravenous iron products, rather than taking one particular product as a central focus of the analysis, and we chose a dichotomous variable, the proportion of patients who responded to intravenous iron therapy, as primary outcome, rather than mean increase in Hb levels, which is a continuous variable. While the superior efficacy of intravenous iron products is unquestioned, safety remains a common concern among physicians, especially in the light of earlier experiences with HMW iron dextran. Modern intravenous iron compounds are more stable and allow only a low level of labile iron to be released into the circulation, resulting in an improved safety profile. Thus, severe or life-threatening anaphylactoid reactions occur only very rarely. According to our systematic review, FCM and IDX were associated with the fewest adverse events, followed by IS and ISM respectively. However, in one of the IDX studies, 46 pre-infusion corticosteroids were administered to 20% of patients, reducing the likelihood of adverse drug reactions; while the authors of that report recommend the routine administration of pre-infusion corticosteroids, this is contrary to recent publications, which do not recommend routine prophylaxis against potential allergic reactions. 61 In all studies included in our analysis, only three serious adverse events were reported for any intravenous iron compounds. Although the composition of specific intravenous iron products differs only marginally, our results indicate that not only efficacy and tolerability but also dosage, duration and frequency of infusions show considerable dissimilarity. All intravenous solutions allow higher doses than are normally possible with oral iron, for which a dose equivalent to 50-200 mg of elemental iron (approximately 100-300 mg ferrous sulphate) per day is recommended. 8 Furthermore, the maximal rate of oral iron absorption has been reported to be only 10-20 mg/dL in iron-deficient patients, 11, 12 so that oral supplementation generally has to be continued for up 5 months, 8 or for a minimum of 3 months after replenishment of iron stores. 62 All studies included in this analysis used 100-200 mg of ferrous iron per day, except for Lindgren et al., 53 who gave 200 mg twice daily. While 200 mg may be considered standard, tolerance and compliance are lower than for 100 mg. 63 Moreover, only ca. 7% of ingested oral iron can be absorbed by the gut, while the remaining 93% may alter the microbiome and cause gut damage, as described above. Findings from a study of the response of irondeficient individuals to daily oral iron suggest that frequent high dosing could cause a paradoxical decrease in iron absorption 64 In this study, 54 women with depleted iron stores (ferritin ≤20 ng/mL) but without anaemia were given various doses of oral iron that contained a traceable isotope to track absorption. Iron absorption was best when dosing was lower and less frequent (e.g. 40-80 mg of iron not more than once a day). Higher or more frequent doses of iron raised circulating hepcidin levels and reduced subsequent fractional iron absorption. Dosage recommendations for the different intravenous compounds vary considerably: For FCM, up to 1000 mg or max. 20 mg/kg BW infused over 15 min once weekly; for IS and LMW-IDX, 100-200 mg infused over ca. 1 h up to three times per week; and for ISM, 20 mg/kg BW infused over ca. 15-30 min up to three times per week. In past general practice, iron requirements were commonly calculated using the Ganzoni formula [iron deficit (mg) = body weight (kg)] x [target HbÀactual Hb (g/dL)] 9 2.4 + 500 mg, 65 which was also the most common dosing regimen in our studies. However, several authors concluded that dose requirements were underestimated, and that response rates could be improved by higher cumulative doses. The dosing schedule for FCM suggested by Evstatiev et al. 22 has been suggested to represent a more accurate estimation of individual iron requirements. This simplified dosing schedule now serves as the basis for dosing recommendations in the Summaries of Product Characteristics (SPCs) for both FCM and ISM. Further studies investigating optimal dosing of intravenous preparations in IBD patients with IDA are required. While intravenous iron is more effective than oral iron, it is also considerably more expensive: Current prices in Germany for 500 mg intravenous iron are approximately 190€ for FCM, 82-105€ for IS, 181€ for ISM and 83-94€ for IDX. The difference in drug costs must also be put into perspective with the costs of medical supervision, practice overheads, and patient travel costs and time lost from work, which depend on the number and duration of infusions. High doses of both FCM and ISM can be quickly administered in rapid infusions lasting only 15 min.
The study also clearly demonstrates that the specific properties of these nanocolloidal drug products (nanomedicines) necessitate detailed evaluation, not only in terms of in vitro quality and nonclinical aspects; there is a need for a head-to-head clinical investigation in patients to define efficacy and tolerability, specific therapeutic utility, and ultimately, the potential therapeutic equivalence of intravenous iron compounds. Such clinical comparisons are a pre-requisite to allow any conclusions on substitutability or interchangeability of drug products or their follow-on versions. This concurs with the European Medicines Agency (EMA) reflection paper on data requirements for intravenous iron-based nanocolloidal products developed with reference to an innovator medicinal product. 66 The present study was based on a rigorous and extensive bibliographical literature search that entailed the inclusion of all published clinical trials focussing on different intravenous iron compounds in the context of IDA therapy in IBD patients. Data extraction and eligibility assessment were independently undertaken by two independent researchers, and eligibility criteria were explicit. We chose to evaluate the available literature by means of response rate (as defined above), a straightforward dichotomous variable, aiming to provide treating physicians with a definite result for reference. The statistical analysis is solid and objective, and incorporates the latest developments in network meta-analysis. Moreover, although the studies had different inclusion and exclusion criteria, clinical outcomes, time horizon and treatment dosing regimens, insignificant heterogeneity was identified across the RCTs used in the network metaanalysis, supporting the robustness of our findings.
The review has a number of limitations, including those typical of systematic searches and indirect comparisons of interventions. First, selection bias may have occurred, since only four databases were searched, and the review adopts any publication bias of the studies included. Although we were unable to access the Embase database, we believe no important study was missed. Clinical outcomes, time horizon and treatment dose were not consistent across the studies, and while heterogeneity of the studies included in the network meta-analysis was found to be insignificant, we have no evidence to show that all 15 studies included in the systematic review show similarly low heterogeneity. Haematological inclusion criteria, and thus baseline Hb values, varied widely; not all trials included patients with mild anaemia. In addition, some did not share our definition of response (Hb normalisation or ≥2 g/dL increase) as a primary outcome.
Adverse event reporting varied considerably between studies, making interpretation of these data, in some cases, challenging. Importantly, the safety analysis was relatively small, including 1673 patients in total, a sample size insufficient to detect a possible signal for rare but potentially serious side effects. Finally, the scope of our research did not allow for the collection and analysis of raw data, but was reliant on published study reports. Thus, heterogeneity and possible reporting bias could not be counteracted, and it was not possible to select or deselect particular participants or subgroups for analysis.
Despite these limitations, the systematic review and network meta-analysis incorporates all currently available evidence concerning intravenous iron replacement in IBD patients with IDA, and to the best of our knowledge, this is the first attempt to systematically and quantitatively review the literature in this field.
CONCLUSION
All four intravenous iron compounds included in the systematic review were found to be safe and effective for the treatment of iron deficiency anaemia in patients with IBD. Ferric carboxymaltose was shown to be the most effective intravenous iron formulation, followed by iron sucrose. Ferric carboxymaltose also tended to be better tolerated, with fewer adverse events. Furthermore, due to its suitability for rapid, high-dose infusion, ferric carboxymaltose is economically on a par with iron isomaltose, higher costs being offset by savings in medical supervision, practice/clinic overheads, patient travel and time lost from work. Further trials are needed to increase the level of evidence available to establish the comparative efficacy of different intravenous iron compounds in IBD patients with iron deficiency anaemia.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Figure S1 . Risk of bias graph: Judgements regarding risk of bias are presented as percentages across all randomised, controlled trials included in network meta-analysis. The figure illustrates, for each considered bias domain, the proportion of studies falling in each category of risk (low risk of bias, unclear risk of bias, high risk of bias). Figure S2 . Network of RCTs included in network meta-analysis. Table S1 . Main features and results of the 15 studies included in the systematic review.
